Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020110089 - UROLITHINE A ET COMPOSITION LA CONTENANT POUR UTILISATION EXTERNE DANS DES INFLAMMATIONS DE DIVERSES ÉTIOLOGIES

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A pharmaceutical composition comprising one or more typical auxiliary substances and an active ingredient, characterized in that it contains urolithin A or a pharmaceutically acceptable derivative thereof as the active ingredient, preferably synthetic urolithin A or a pharmaceutically acceptable derivative thereof for use in the treatment, inhibition and prevention of inflammatory diseases of skin and/or mucous membranes.

2. The pharmaceutical composition according to claim 1, wherein said active ingredient is a urolithin A derivative selected from the group consisting of urolithin A 3 -formate, urolithin A 8-acetate, urolithin A 3-acetate, urolithin A 3,8-diacetate, urolithin A 8-propionate, urolithin A 8-butyrate, urolithin A 3,8-diisobutyrate, urolithin A 3,8-disalicylate, urolithin A 8-benzoate, urolithin A 8-citrate, urolithin A 8-stearate, urolithin A 3,8-palmitate, urolithin A 8-oleate, urolithin A 3,8-didodecanoate, preferably from the group of diacylated derivatives.

3. The pharmaceutical composition according to claim 2, wherein said active ingredient is urolithin A 8-acetate, urolithin A 3-acetate and urolithin A 3,8-diacetate, preferably urolithin A 3,8-diacetate.

4. The pharmaceutical composition according to any one of the preceding claims 1-3, wherein said active ingredient is present in the amount from about 0.0001 weight percent to about 15 weight percent based on the total weight of the composition, preferably from about 0.01 weight percent to about 5 weight percent based on the total weight of the composition, more preferably from about 0.1 weight percent to about 2 weight percent based on the total weight of the composition, most preferably 1 weight percent based on the total weight of the composition.

5. The pharmaceutical composition according to any one of the preceding claims 1-4, which further contains at least one drug selected from the group of steroids, calcineurin

inhibitors, drugs with antibacterial, antifungal or antiviral activity, preferably selected from the group of steroids or calcineurin inhibitors, most preferably the drug is a calcineurin inhibitor.

6. The pharmaceutical composition according to any one of the preceding claims 1-5, wherein urolithin A is the only active ingredient present in the composition.

7. The pharmaceutical composition according to any one of the preceding claims 1-6, wherein said at least one pharmaceutically acceptable auxiliary substance is selected from a carrier and/or an excipient and/or a diluent and combinations thereof.

8. The pharmaceutical composition according to any one of the preceding claims 1-7, wherein said pharmaceutically acceptable auxiliary substance is one or more of protective agents, adsorbents, demulcents, emollients, preservatives, antioxidants, moisturizers, buffering agents and solubilizing agents.

9. The pharmaceutical composition according to any one of the preceding claims 1-8, which composition is intended for external administration.

10. The pharmaceutical composition according to claim 9, which composition is intended for topical administration.

11. The pharmaceutical composition according to claim 10, wherein the diseased area being in the range from about 0.0001 g/cm2 of skin surface area to about 0.5 g/cm2, preferably from 0.001 g/cm2 to about 0.2 g/cm2 skin surface area.

12. The pharmaceutical composition according to any one of claims 1-11, said composition is in a liquid form, preferably in the form of a tonic, balm, lotion, foam, most preferably in the form of a tonic.

13. The pharmaceutical composition according to any one of claims 1-11, wherein said composition is in a semi-solid form, preferably in the form of an ointment, cream, paste, gel, preferably in the form of an ointment or cream, most preferably in the form of an ointment.

14. The pharmaceutical composition according to claim 12 or 13, wherein said composition is intended to be applied to the diseased area manually, preferably using a dropper, application stick or spray applicator.

15. The pharmaceutical composition according to any one of claims 1-11, wherein said composition is in the form of a transdermal therapeutic system such as an intradermal patch or a transdermal patch.

16. The pharmaceutical composition for use according to any one of the preceding claims 1-15, wherein inflammatory disease of skin and/or mucous membranes is selected from the group consisting of skin inflammations, vasculitides, lupus erythematosus, dermatomyositis, scleroderma, multiple sclerosis, giant cell arteritis, psoriasis, atopic

dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, rosacea, dermatitis herpetiformis, lichen planus, hidradenitis suppurativa, pityriasis rosea of Gibert, hydrocystoma, aphthae, diaper dermatitis, adolescent acne, non-allergic contact eczema, panniculitis, cellulitis.

17. The pharmaceutical composition for use according to claim 16, wherein said disease of skin and/or mucous membranes is psoriasis.

18. The pharmaceutical composition for use according to claim 16, wherein said disease of skin and/or mucous membranes is atopic dermatitis.

19. Use of a pharmaceutical composition as defined in any one of the preceding claims 1-18, for the treatment of a disease of skin and/or mucous membranes selected from the group consisting of skin inflammations, vasculitides, lupus erythematosus, dermatomyositis, scleroderma, multiple sclerosis, giant cell arteritis, psoriasis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, rosacea, dermatitis herpetiformis, lichen planus, hidradenitis suppurativa, pityriasis rosea of Gibert, hydrocystoma, aphthae, diaper dermatitis, adolescent acne, non-allergic contact eczema, panniculitis, cellulitis.

20. Use according to claim 19 characterized in that the disease of skin and/or mucous membranes is psoriasis.

21. Use according to claim 19 characterized in that the disease of skin and/or mucous membranes is atopic dermatitis.